Blog - Page 3501 of 5672

FridayApr 01, 2011 10:20 am

China Biologic Products, Inc. (CBPO) Reports Record Annual Sales and Net Income

China Biologic Products, the largest non-state-owned plasma based biopharmaceutical company in China, has reported record sales and net income for the year ended December 31, 2010. Sales for the Shandong Province based company increased 17.4% to $139.7 million for the year, compared to $119.0 million in 2009. Non-GAAP adjusted net income was $39.0 million for 2010, compared with $31.5 million for 2009. The company indicated that the revenue increase was due primarily to a general increase in the price and volume of plasma based products. Sales from human albumin product increased approximately 13.4% to $67.1 million, accounting for approximately 48.0%…

FridayApr 01, 2011 9:30 am

Coates International Ltd. (COTE) Signs Letter of Intent to Merge with Chinese Firm

Coates International Ltd. has spent over 15 years developing a patented spherical rotary valve CSRV internal combustion engine. This engine runs on a number of different fuels including gasoline, natural gas, ethanol, methanol, diesel and hydrogen. The engine has reduced maintenance requirements, reduced fuel consumption, reduced emissions and increased power. The company announced today that it has signed a letter of intent to merge with an industrial engine and generator manufacturing company in China. The merger is subject to certain conditions and governmental approvals, including raising capital internationally. The Chinese manufacturer currently employs more than 2,000 skilled plant workers and…

FridayApr 01, 2011 8:51 am

VIASPACE, Inc. (VSPC) Posts Q4, FY2010 Results reflecting Substantial Increase in Revenues

VIASPACE Inc., a clean energy company focused on providing products and technology for renewable and alternative energy, today reported its financial results for the fourth-quarter and year ended December 31, 2010. Fourth quarter 2010 total revenues were reported at $1,040,000, up more than 22% from the $851,000 that was reported for the same period in 2009. Cost of revenues totaled $752,000 in Q4 2010, compared to $541,000 in Q4 2009. Gross profit for the quarter was $288,000, compared to gross profit of $310,000 a year earlier. Total operating expenses for the quarter were $922,000, including $860,000 of selling, general and…

FridayApr 01, 2011 8:33 am

Apthera Announces Merger Agreement with RXi Pharmaceuticals (RXII)

Yesterday, Apthera Inc. announced that it has entered into a merger agreement with RXi Pharmaceuticals Corp., who will acquire Apthera. The merger will help initiate the Phase III trial for the new breast cancer drug NeuVax. NeuVax is a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer patients who can't take Herceptin. It is expected to enter Phase III clinical trials in 2012, under an FDA approved Special Protocol Assessment. Apthera, Inc. is a biotech company that is developing and commercializing a series of immunotherapies for the treatment of HER2-positive cancers. Apthera's products are currently in clinical trials, which are attempting…

FridayApr 01, 2011 8:31 am

Jammin Java Corp. (JAMN) Products Now Available on Amazon.com

Jammin Java Corp. announced yesterday that it will be selling its fresh roasted premium line of gourmet fair trade organic coffee on Amazon.com, the largest online retailer in the United States. The company will sell 2.2 lb whole bean bags of its three flavors: Kingston City Espresso, Lion’s Blend and Mountain Roast Decaf. The Lion’s Blend and Mount Roast Decaf are also available in the company’s line of perfect pot coffees (2.5 oz ground fractional packs). The perfect packs, great for in home or office use, will be available on Amazon.com shortly. Anh Tran, CEO of Jammin Java Corp, remarked,…

FridayApr 01, 2011 8:29 am

OurPet’s Co. (OPCO) takes Bite of Booming Pet Industry with Strategic Positioning

Ohio-based OurPet’s Co. launched its operations in 1995 with the development of Big Dog Feeder and has since developed a successful line of pet products catering to the health, behavioral and lifestyle needs of pets. The company has 52 granted or assigned U.S. patents for its dog and cat feeders, as well as 54 U.S. patents pending for cat and dog toys, dog feeders, and natural and nutritional pet supplements and treats. According to the U.S. Census Bureau, the pet industry is the seventh largest retail segment in the country. The industry overshadows the toy industry by 60 percent, and…

FridayApr 01, 2011 7:51 am

Avanir Pharmaceuticals (AVNR) Video Chart for Friday, April 1, 2011

AVNR is making a rounded bottom after a lengthy consolidation. The share price is currently at resistance and on the radar for a breakout or a possible small pullback to create a double bottom on nearby support before potentially taking another run at resistance. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts.php Let us hear your thoughts below:

ThursdayMar 31, 2011 2:57 pm

Force Energy Corp. (FORC) is “One to Watch”

Force Energy Corp., based in Denver, Colorado, is one of a handful of intelligent companies getting into lithium production in North America and is also a developer of hydrocarbons. The cornerstone of the emerging hybrid and electric vehicle market, which stands to be huge globally, and much of the personal and portable technology modern civilization runs on, requires lithium for the lithium-ion (Li-ion) batteries that sustain or supply power. Other end markets like ceramics, especially industrial process ceramics and the like, as well as glass, lubricating greases and other products, make lithium an extremely hot commodity when one considers the…

ThursdayMar 31, 2011 2:31 pm

RXi Pharmaceuticals Corp. (RXII) Signs Definitive Merger to Acquire Apthera Inc. for Late Stage-Clinical Development

RXi Pharmaceuticals Corp., a discovery-stage biopharmaceutical company that focuses on the development and commercialization of proprietary therapeutics on RNA interference, has announced the signing of a definitive merger agreement to acquire Apthera, Inc., a private biotechnology company that develops a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers. The acquisition will provide RXi with a late stage product candidate, NeuVax™, which is a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, not eligible for Herceptin®, which has been expected to enter Phase III clinical trials by the first half of 2012. The company’s very first…

ThursdayMar 31, 2011 1:25 pm

UniTek Global Services Inc. (UNTK) Posts 49% Increase in Q4 Earnings, Offers 2011 Guidance

UniTek Global Services Inc., a leading provider of various infrastructure services to the wireless and wireline telecommunications, broadband cable and satellite television industries, today announced financial results for the fourth quarter and year ended December 31, 2010, and provided financial guidance for the first quarter and full year 2011. Fourth-quarter revenue increased 49 percent to $100.6 million for the quarter ended December 31, 2010, from $67.6 million in the quarter ended December 31, 2009. Net loss for the quarter was $(12.1 million) compared to a net loss of $(41.9 million) reported in the fourth quarter of 2009. For the full…

Site Search

Company Search